“Research and development (R&D) plays an essential role in developing new treatments, devices and methods of managing disease and constantly strives to improve the effectiveness of existing treatment. However, the benefits of R&D extend well beyond this and it is well documented that research active organisations have improved clinical outcomes, attract and retain high quality staff and can capitalise on an additional income streams.”
Dr Celia Skinner – Chief medical officer, Basildon and Thurrock University Hospitals Trust, Mid-Essex Hospitals Trust and Southend University Hospital Trust.
Research and development is led by our associate director Ashley Solieri under the clinical direction of Dr Rajesh Aggarwal.
We deal with all aspects of clinical research and development, including NHS Permissions, setting up studies, ethic applications, commercial and non-commercial research (original researcher led and student work), grant funding, and innovation and intellectual property. With our partnerships we provide a comprehensive service.
Providing high quality research can improve outcomes for patients; this is at the centre of what we do. Research is embedded in the care we provide at the Trust and we aim to offer every patient the opportunity to take part in research.
Our aim is to increase the number of studies we can offer to our patients, and to help them understand more about research and what it means to the NHS.
Our researchers lead and contribute to world class research which helps us to understand diseases better and develop new treatments for the benefit of patients and the NHS.
Meet the team
Clinical director, research and development
Dr Rajesh Aggarwal
01268 524900 ext. 4092
Consultant Cardiologist and Clinical Director of R&D providing strategic and clinical direction.
Associate director, research and development
Ms Ashley Solieri
Leading strategic and general management of the Trust’s R&D profile and the R&D Department. Also the named accountable officer for research and commercial innovation activity and service evaluation.
Research quality facilitator
01268 524900 ext 3599
First point of contact for researcher led studies (including student studies); experienced in research design and ethics applications.
Senior clinical trials practitioner
01268 524900 ext 8384
First point of contact for all NIHR adopted studies, research nurse capacity and Good Clinical Practice (GCP) training.
01268 524900 ext 4672
Undertakes study feasibility; experienced in contracts, costing and budget negotiations.
General enquires, site file maintenance, close out and archiving
There is a national ambition to see a dramatic and sustained improvement in the performance of providers of NHS services in initiating and delivering clinical research. The aim is to increase the number of patients who have the opportunity to participate in research and to enhance the nation’s attractiveness as a host for research.
The Government’s Plan for Growth, announced the transformation of incentives at local level for efficiency in initiation and delivery of research.
Our Trust publishes clinical research outcomes against two public benchmarks:
Initiating research – the time R&D takes setting-up a research study; up to 70 days from the time we receive a valid research application to the time we recruit the first patient into that study
Delivering research – for commercial contract clinical studies hosted by us, the time we took to recruit our first patient to the study against our projected recruitment.
All performance documentation can be seen the Research and Development 'documents' section.
Research cannot operate in isolation and involves a great deal of collaboration to achieve optimal results. Our key collaborators are:
The National Institute for Health Research
The NIHRis funded through the Department of Health to improve the health and wealth of the nation through research.
The National Institute for Health Research, Clinical Research Network (CRN)
Funded via the NIHR, the Clinical Research Network (CRN) comprises of 15 local CRN that cover England. Each local CRN supports its member trust in delivering research studies. We are part of North Thames CRN (NT; CRN).
The Health Research Authority (HRA)
The HRA protects and promotes the interests of patients and the public in health research, and to streamline the regulation of research.
The HRA provide an ethical opinion on research conducted in the NHS.
Anglia Ruskin University (ARU)
ARU is one of the largest universities in the east of England. Our two partners within ARU are the School of Medicine and Anglia Ruskin Clinical Trials Unit (ARCTU). Our Joint Cardiology Research Unit with ARU is supporting several Doctor of Medicine (MD) fellows, a PhD student and two senior research fellows. The Associate Director works closely with ARU is an Honorary Visiting Fellow of the School of Medicine and is the expert external member of the university’s Research Ethics Sub Committee.
International Clinical Trials Day Friday 19th May 2017
The R&D team are celebrating International Clinical Trials Day on Friday 19th May 2017 with the launch of their “consent to contact” initiative. The team will be in the main entrance to the hospital highlighting the work they do and celebrating the valuable contribution of the volunteers that take part in research.
Please visit the stand to find out more
Dementia Research Challenge
Through the National Institute for Health Research (NIHR), £22 million of additional funding is going into twenty-one pioneering research projects.
TACIT Trial results
Rheumatoid arthritis (RA) is a common condition causing pain through inflammation of the joints with progressive joint damage leading to disability.
Tumour necrosis factor inhibitor (TNF) is an innovative biological new drug treatment for RA but is very expensive with the treatment needed indefinitely as it suppresses RA rather than cures it.
Due to their cost, current guidance for the use of TNF is to limit its use to patients who have not responded to treatment by two standard synthetic RA drugs.
Previous evidence had shown that the use of a combination of conventional synthetic anti-rheumatic drug treatments could be effective and offer an alternative approach to treating patients with very active RA. This approach could offer an effective treatment for patients at a lower cost, potentially making resources available to fund TNF drugs in areas where it is not currently offered.
The TACIT trial recruited 432 patients to compare TNF against a combination treatment of conventional anti-rheumatic drugs. A randomised total of 205 patients were treated with TNF drugs with the remaining patients receiving the combination drug treatment.
The trial found the combination synthetic drug treatment was no less effective than treatment with the more expensive biological TNF drugs.
Dr Gendi and research nurses at Basildon Hospital was one of the sites running this NIHR funded study.
Diabetes research – September
Ian Luder, previous chairman of the Trust, (pictured with Research Nurse Natasha Christmas and Clinical Trials Practitioner Georgina Butt) has diabetes and is an enthusiastic volunteer and champion of the DARE research.
He said: “It is only by doing research that new treatments can be developed, so I am pleased to be able to apply my condition to help.”
Dr Farooq Maniyar, Consultant Neurologist, won the Harold G. Wolff Lecture Award 2013, given by the American Headache Society for the most significant original research in headache medicine of the year.
R&D celebrate International Clinical Trials Day and ‘It’s OK to ask’ campaign – May
Ashley Solieri, Associate Director of Research and Annaliza Sevillano, Cardiology RN Nurse.